Holen Sie sich die Stockscreener-App
48.22
0.21%
0.10
Handel nachbörslich:
48.22
Schlusskurs vom Vortag:
$48.12
Offen:
$47.68
24-Stunden-Volumen:
458.06K
Relative Volume:
0.60
Marktkapitalisierung:
$2.35B
Einnahmen:
$140.49M
Nettoeinkommen (Verlust:
$-153.49M
KGV:
-17.50
EPS:
-2.7551
Netto-Cashflow:
$-175.90M
1W Leistung:
+2.68%
1M Leistung:
+23.04%
6M Leistung:
+139.90%
1J Leistung:
+140.14%
1-Tages-Spanne:
$46.62
$48.48
1-Wochen-Bereich:
$45.34
$49.67
52-Wochen-Spanne:
$15.86
$49.67
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
48.22 | 2.39B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN - marketbeat.com
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence? - simplywall.st
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice - Yahoo Finance
UroGen Pharma Ltd (URGN) Competitors 2026 - GuruFocus
(URGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
UroGen Pharma (URGN): TD Bank group discloses 3.37M shares, 6.9% beneficial stake - Stock Titan
UroGen (URGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year HighTime to Buy? - marketbeat.com
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed? - Sahm
Urogen Pharma Ltd at TD Cowen Healthcare Conference Transcript - GuruFocus
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
UroGen Pharma Ltd. (URGN) Options Chain - Yahoo! Finance Canada
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - marketbeat.com
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run - Sahm
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus - Yahoo Finance
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed - Yahoo Finance
UroGen Pharma Ltd. Revenue Breakdown – MUN:UR8 - TradingView
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts - simplywall.st
URGN Stock Price, Quote & Chart - ChartMill
Oppenheimer Adjusts PT on UroGen Pharma to $60 From $50, Maintains Outperform Rating - Moomoo
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - 富途牛牛
Guggenheim raises UroGen Pharma stock price target to $58 on sales beat - Investing.com South Africa
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75 - 富途牛牛
URGN Maintained by Guggenheim -- Price Target Raised to $58.00 - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given New $75.00 Price Target at HC Wainwright - marketbeat.com
URGN Maintains Buy by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - Moomoo
URGN SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
URGN Maintained by TD Cowen -- Price Target Raised to $60 - GuruFocus
UroGen Pharma Ltd (URGN) (Q2 2026) Earnings Call Highlights: Cys - GuruFocus
Urogen Pharma Q2 Earnings Call Highlights - Yahoo Finance
Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1%Here's Why - MarketBeat
UroGen Pharma Posts 199% Revenue Jump in Q2 2026, Misses on EPS - AlphaStreet
UroGen Pharma 2Q Loss $14.4M >URGN - moomoo.com
Urogen Pharma stock hits 52-week high at 43.97 USD - Investing.com
Earnings call transcript: UroGen Pharma tops Q2 2026 revenue forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: UroGen Pharma tops Q2 2026 revenue forecast - Investing.com
Urogen Pharma stock hits 52-week high at 43.97 USD By Investing.com - Investing.com South Africa
UroGen Pharma Q2 Net Loss Narrows, Revenue Rises - Moomoo
Is UroGen Pharma Ltd (URGN) Overvalued Despite Q2 Revenue of $72 - GuruFocus
Q2 2026 Urogen Pharma Ltd Earnings Call Transcript - GuruFocus
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
UroGen Pharma 2Q Loss/Shr 28c >URGN - Moomoo
Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $0.28 a Share, vs. FactSet Est of $0.27 Loss - marketscreener.com
UroGen Q2 revenue jumps to $72.5 million on ZUSDURI launch - Quiver Quantitative
UroGen Reports $72.5M Q2 Revenue, $50.4M ZUSDURI Sales and $14.4M Net Loss - TradingView
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights - marketscreener.com
Press Release: UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights - Moomoo
Q2 2025 Urogen Pharma Ltd Earnings Call Transcript - GuruFocus
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):